Signature Gene Mutations in Colorectal Cancer: Potential Neoantigens for Cancer Vaccines DOI Open Access
Jong‐Seo Yoon,

Haeun Moon,

Yong Tark Jeon

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(10), P. 4559 - 4559

Published: May 9, 2025

Colorectal cancer (CRC), the third most common worldwide, is one of deadliest cancers. CRC known as a cold tumor, characterized by low immune response that makes it difficult for cells to infiltrate and exhibits strong resistance immunotherapy with checkpoint inhibition. This restricted largely attributed signature gene mutations including mismatch repair (MMR) genes, KRAS, BRAF, APC, TP53, which are also main oncogenes in CRC. Mutated genes continuously upregulate abnormal signaling pathways, leading excessive proliferation, progression, metastasis. Furthermore, reorganizes tumor microenvironment (TME) recruiting immunosuppressive cells. However, mutation can produce neoantigens provoke an response, making potential target immunotherapy. In particular, vaccines leverage neoantigenic properties these considered promising overcoming eliciting anti-tumor responses. this review, we will describe focus on targeting therapies

Language: Английский

Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate DOI Creative Commons

Uttpal Anand,

Anustup Bandyopadhyay,

Niraj Kumar Jha

et al.

BioFactors, Journal Year: 2022, Volume and Issue: 49(2), P. 251 - 269

Published: Nov. 3, 2022

Abstract In the last two decades, protein–protein interactions (PPIs) have been used as main target for drug development. However, with larger or superficial binding sites, it has extremely difficult to disrupt PPIs small molecules. On other hand, intracellular cannot be targeted by antibodies that penetrate cell membrane. Peptides a combination of conformational rigidity and flexibility can interfaces appropriate affinity specificity. Since introduction insulin nearly century ago, more than 80 peptide drugs approved treat variety diseases. These include deadly diseases such cancer human immunodeficiency virus infection. It is also useful against diabetes, chronic pain, osteoporosis. Today, research being done on these lessons learned from earlier approaches, which are still valid today, complement newer approaches display libraries. At same time, integrated genomics libraries new strategies open avenues discovery. The purpose this review examine problems in elucidating peptide‐protein recognition mechanism. This important develop peptide‐based interventions interfere endogenous protein interactions. New developed improve specificity existing agents potentially drugs. We highlight key challenges must overcome development realize their potential provide an overview recent trends addition, we take in‐depth look at early efforts hormone discovery, smart medicinal chemistry design, natural drugs, breakthrough advances molecular biology chemistry.

Language: Английский

Citations

40
Advanced technologies for the development of infectious disease vaccines DOI
Akash Gupta, Arnab Rudra,

Kaelan Reed

et al.

Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: 23(12), P. 914 - 938

Published: Oct. 21, 2024

Language: Английский

Citations

11
A computational approach to design a multiepitope vaccine against H5N1 virus DOI Creative Commons
Fatemeh Dashti,

Arash Raisi,

Ghazaleh Pourali

et al.

Virology Journal, Journal Year: 2024, Volume and Issue: 21(1)

Published: March 20, 2024

Abstract Since 1997, highly pathogenic avian influenza viruses, such as H5N1, have been recognized a possible pandemic hazard to men and the poultry business. The rapid rate of mutation H5N1 viruses makes whole process designing vaccines extremely challenging. Here, we used an in silico approach design multi-epitope vaccine against A virus using hemagglutinin (HA) neuraminidase (NA) antigens. B-cell epitopes, Cytotoxic T lymphocyte (CTL) Helper (HTL) were predicted via IEDB, NetMHC-4 NetMHCII-2.3 respectively. Two adjuvants consisting Human β-defensin-3 (HβD-3) along with pan HLA DR-binding epitope (PADRE) chosen induce more immune response. Linkers including KK, AAY, HEYGAEALERAG, GPGPGPG double EAAAK utilized link epitopes adjuvants. This construct encodes protein having 350 amino acids 38.46 kDa molecular weight. Antigenicity ~ 1, allergenicity non-allergen, toxicity negative solubility appropriate confirmed through Vaxigen, AllerTOP, ToxDL DeepSoluE, 3D structure was refined validated Z-Score − 0.87 overall Ramachandran 99.7%. Docking analysis showed could interact TLR7 (docking score 374.08 by 4 hydrogen bonds) TLR8 414.39 3 bonds). Molecular dynamics simulations results RMSD RMSF 0.25 nm 0.2 for H5N1-TLR7 well 0.45 0.4 H5N1-TLR8 complexes, Mechanics Poisson-Boltzmann Surface Area (MM/PBSA) stability continuity interaction between total binding energy 29.97 kJ/mol 23.9 kJ/mol. Investigating response simulation evidence ability stimulate B cells immunity system that shows merits this proposed candidate clinical trials.

Language: Английский

Citations

10
Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines DOI Creative Commons
Dang-Khoa Vo, Kieu The Loan Trinh

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 191 - 191

Published: Feb. 15, 2025

Using plants as bioreactors, molecular farming has emerged a versatile and sustainable platform for producing recombinant vaccines, therapeutic proteins, industrial enzymes, nutraceuticals. This innovative approach leverages the unique advantages of plants, including scalability, cost-effectiveness, reduced risk contamination with human pathogens. Recent advancements in gene editing, transient expression systems, nanoparticle-based delivery technologies have significantly enhanced efficiency versatility plant-based systems. Particularly vaccine development, demonstrated its potential notable successes such Medicago's Covifenz COVID-19, illustrating capacity platforms to address global health emergencies rapidly. Furthermore, edible vaccines opened new avenues mainly settings low resources where cold chain used conventional logistics is challenge. However, optimization protein yield stability, complexity purification processes, regulatory hurdles are some challenges that still remain. review discusses current status development using operational mechanisms plant platforms, major applications prevention infectious diseases, developments, nanoparticle-mediated cancer vaccines. The discussion will also touch on ethical considerations, framework, future trends respect transformative plant-derived ensuring greater accessibility cost-effectiveness vaccination. field holds great promise disease area and, indeed, personalized medicine biopharmaceuticals near future.

Language: Английский

Citations

1
In Silico Studies to Support Vaccine Development DOI Creative Commons
Leonor Saldanha, Ülo Langel, Nuno Vale

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(2), P. 654 - 654

Published: Feb. 15, 2023

The progress that has been made in computer science positioned silico studies as an important and well-recognized methodology the drug discovery development process. It numerous advantages terms of costs also plays a huge impact on way research is conducted since it can limit use animal models leading to more sustainable research. Currently, human trials are already being partly replaced by trials. EMA FDA both endorsing these have providing webinars guidance support them. For instance, PBPK modeling used gather data interactions with other drugs clinical regulatory requirements for pediatric population, pregnant women, personalized medicine. This trend evokes need understand role vaccines, considering importance products achieved during pandemic their promising hope oncology. Vaccines safer than current oncology treatments. There variety strategies developing cancer vaccine, some points should be considered when designing vaccine technology following: delivery platforms (peptides, lipid-based carriers, polymers, dendritic cells, viral vectors, etc.), adjuvants (to boost promote inflammation at site, facilitating immune cell recruitment activation), choice targeted antigen, timing vaccination, manipulation tumor environment, combination treatments might cause additive or even synergistic anti-tumor effects. These many put together outline best design. aim this article perform review comprehensive analysis design vaccines field infectious diseases. authors intend literature all so far preparing methods vaccines. From point, was possible conclude there few Despite this, overview how existing work could described.

Language: Английский

Citations

18
Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective DOI Creative Commons

S. Furkan Demirden,

Ilgin Kimiz‐Gebologlu, Suphi Ş. Öncel

et al.

ACS Omega, Journal Year: 2024, Volume and Issue: unknown

Published: April 2, 2024

Vaccines are considered the most effective tools for preventing diseases. In this sense, with Covid-19 pandemic, effects of which continue all over world, humanity has once again remembered importance vaccine. Also, various epidemic outbreaks that occurred previously, development processes vaccines against these viral pathogens have accelerated. By efforts, many different new vaccine platforms been approved commercial use and introduced to landscape. addition, innovations made in production carried out conventionally produced types create a rapid response prevent potential epidemics or pandemics. situation, cell lines being positioned at center generation as expression platforms. Therefore, since main goal is produce fast, safe, disease, addition existing systems, not used until now included first time. review, current clinical today described. Then, reason using lines, vaccines, general culture-based mentioned. selection parameters animal explained by considering bioprocess efficiency regulations. Finally, their properties summarized, an emphasis on future status cultures industrial production.

Language: Английский

Citations

7
Recent Progress in Cancer Vaccines and Nanovaccines DOI
Kishwor Poudel,

Tulasi Vithiananthan,

Jong Oh Kim

et al.

Biomaterials, Journal Year: 2024, Volume and Issue: 314, P. 122856 - 122856

Published: Sept. 28, 2024

Language: Английский

Citations

5
Extracellular vesicles-based vaccines: Emerging immunotherapies against cancer DOI Creative Commons

Yuhua Meng,

Zhimeng Yao,

Xiurong Ke

et al.

Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 378, P. 438 - 459

Published: Dec. 21, 2024

Cancer vaccines are promising therapeutic approaches to enhance specific T-cell immunity against most solid tumors. By stimulating anti-tumor immunity, clearing minimal residual disease, and minimizing adverse effects, these target tumor cells effective when combined with immune checkpoint blockade or other immunotherapies. However, the development of cell-based faces quality issues due poor immunogenicity, heterogeneity, a suppressive microenvironment, ineffective delivery methods. In contrast, extracellular vesicles (EVs), naturally released by cells, considered ideal drug carriers vaccine platforms. EVs offer highly organ-specific targeting, induce broader more responses, demonstrate superior tissue ability. The EV is crucial for advancing cancer immunotherapy. Compared vaccines, produced under Good Manufacturing Practices (GMP) advantages such as high safety, ease preservation transport, wide range sources. This review summarizes latest research findings on potential applications in this field. It also highlights novel neoantigens cancer.

Language: Английский

Citations

5
Smart therapies against global pandemics: A potential of short peptides DOI Creative Commons
Vasso Apostolopoulos, Joanna Bojarska, Jack Feehan

et al.

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: Aug. 15, 2022

OPINION article Front. Pharmacol., 15 August 2022Sec. Drugs Outcomes Research and Policies https://doi.org/10.3389/fphar.2022.914467

Language: Английский

Citations

21
Nano-carrier DMSN for effective multi-antigen vaccination against SARS-CoV-2 DOI Creative Commons
Peng Sun,

Bingsheng Cheng,

Jiaxi Ru

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Jan. 3, 2024

Abstract The pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has had a profound impact on the global health and economy. While mass vaccination for herd immunity is effective, emerging SARS-CoV-2 variants can evade spike protein-based COVID-19 vaccines. In this study, we develop new immunization strategy utilizing nanocarrier, dendritic mesoporous silica nanoparticle (DMSN), to deliver receptor-binding domain (RBD) conserved T-cell epitope peptides (DMSN-P-R), aiming activate both humoral cellular immune responses in host. synthesized DMSN good uniformity dispersion showed strong ability load RBD peptide antigens, enhancing their uptake antigen-presenting cells (APCs) promoting antigen delivery lymph nodes. DMSN-P-R vaccine elicited potent immunity, characterized highly specific antibodies. Neutralization tests demonstrated significant antibody-mediated neutralizing activity against live SARS-CoV-2. Crucially, also induced robust that were specifically stimulated of excellent biocompatibility biosafety vitro vivo, along with degradability. Our study introduces promising utilizes nanocarriers range effectively prevent virus transmission.

Language: Английский

Citations

4